- Home
- DOUG vs INBX Comparison
DOUG vs INBX Comparison
Compare DOUG & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- INBX
- Stock Information
- Founded
- DOUG 1911
- INBX 2010
- Country
- DOUG United States
- INBX United States
- Employees
- DOUG N/A
- INBX N/A
- Industry
- DOUG Building operators
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- DOUG Real Estate
- INBX Health Care
- Exchange
- DOUG Nasdaq
- INBX Nasdaq
- Market Cap
- DOUG 166.2M
- INBX 237.5M
- IPO Year
- DOUG N/A
- INBX 2020
- Fundamental
- Price
- DOUG $1.84
- INBX $16.28
- Analyst Decision
- DOUG
- INBX Hold
- Analyst Count
- DOUG 0
- INBX 1
- Target Price
- DOUG N/A
- INBX N/A
- AVG Volume (30 Days)
- DOUG 663.4K
- INBX 124.6K
- Earning Date
- DOUG 11-05-2024
- INBX 08-13-2024
- Dividend Yield
- DOUG N/A
- INBX N/A
- EPS Growth
- DOUG N/A
- INBX N/A
- EPS
- DOUG N/A
- INBX 118.83
- Revenue
- DOUG $951,674,000.00
- INBX $1,687,000.00
- Revenue This Year
- DOUG $3.85
- INBX N/A
- Revenue Next Year
- DOUG $17.40
- INBX N/A
- P/E Ratio
- DOUG N/A
- INBX $0.15
- Revenue Growth
- DOUG N/A
- INBX 24.26
- 52 Week Low
- DOUG $1.00
- INBX $10.80
- 52 Week High
- DOUG $3.16
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- DOUG 51.03
- INBX 58.50
- Support Level
- DOUG $1.42
- INBX $14.51
- Resistance Level
- DOUG $2.05
- INBX $17.60
- Average True Range (ATR)
- DOUG 0.15
- INBX 0.91
- MACD
- DOUG 0.00
- INBX 0.13
- Stochastic Oscillator
- DOUG 67.20
- INBX 53.96
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.